[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100367735":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":32,"locations":41,"responsibleParty":74,"collaborators":20,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":20,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":20,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":44,"whyStopped":20,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Alpha Tau Medical LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DaRT Seeds Intratumoral Diffusing alpha-emitters","EXPERIMENTAL","An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.",[13],"Device: DaRT- Diffusing Alpha-emitters Radiation Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","DaRT- Diffusing Alpha-emitters Radiation Therapy","Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles",[9],null,[22,26,29],{"name":23,"affiliation":24,"role":25},"Dr Pascal POMMIER","Centre Leon Berard","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Pr Jean Michel HANNOUN LEVI","Antoine Lacassagne Cancer Center",{"name":30,"affiliation":31,"role":25},"Dr Camille VERRY","University Hospital, Grenoble",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":20,"email":37},"Liron Dimnik","CONTACT","+972-2-373-7000","LironD@alphatau.com",{"name":39,"role":35,"phone":20,"phoneExt":20,"email":40},"Amnon Gat","Amnong@alphatau.com",[42,60],{"facility":43,"status":44,"city":45,"state":20,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"CHU Grenoble Alpes","RECRUITING","Grenoble","38700","France","FR",{"type":50,"coordinates":51},"Point",[52,53],5.71479,45.17869,{"lat":53,"lon":52},[56],{"name":57,"role":35,"phone":58,"phoneExt":20,"email":59},"M. Camille Verry, MD","33 (0) 476765435","cverry@chu.grenoble.fr",{"facility":61,"status":44,"city":62,"state":20,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Centre Léon Bérard","Lyon","69008",{"type":50,"coordinates":65},[66,67],4.84789,45.74906,{"lat":67,"lon":66},[70],{"name":71,"role":35,"phone":72,"phoneExt":20,"email":73},"POMMIER Pascal, MD","33 (0) 478785166","pascal.pommier@lyon.unicancer.fr",{"type":75,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100367735","alpha-radiation-emitters-device-dart-for-the-treatment-of-of-malignant-cutaneous-tumors-100367735",false,"NCT04068155","Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors","A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous Tumors","Inclusion Criteria:\n\n* Subjects with histopathological confirmation of newly diagnosed (Cohort A) or locally recurrent (Cohort B) malignant cutaneous lesions of the following histopathologies:\n\n  * SCC\n  * BCC\n  * Lentigo maligna melanoma (Dubreuilh melanoma)\n  * Carcinosarcoma\n* Acceptable tumor locations include the following:\n\n  * Skin (facial, scalp, extremities, torso)\n  * Lips\n  * Eyelids\n* Subjects with a tumor size ≤ 7 centimeters in the longest diameter.\n* Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds.\n* Measurable disease according to RECIST v1.1.\n* Subjects over 18 years old.\n* Subjects' ECOG Performance Status Scale is \\\u003C 2.\n* Subjects' life expectancy is more than 6 months.\n* Platelet count ≥100,000\u002Fmm3.\n* International normalized ratio of prothrombin time ≤1.8.\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.\n* Subjects are willing to sign an informed consent form\n\nExclusion Criteria:\n\n* Subject has a tumor with histology of one of the following:\n\n  * Keratoacanthoma\n  * Merkel cell carcinoma\n  * Sarcoma other than carcinosarcoma\n* Metastatic disease (according to the TNM staging system - M1 patients are excluded)\n* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.).\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Subjects not willing to sign an informed consent.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":86,"type":87},80,"ESTIMATED","INTERVENTIONAL",[90],"NA","A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors",[93,94,95],"Skin Cancer","Cutaneous Tumor","Cutaneous Metastasis",[97,98,93,99,100,101,102,103,104,105,106,107,108,109,110],"Squamous Cell Carcinoma","Basal Cell Carcinoma","Skin Metastasis","Superficial Sarcoma","Alpha Radiation","Cutaneous Lesion","Brachytherapy","Radiotherapy","Lentigo maligna melanoma","Carcinosarcom","scalp cancer","Lip cancer","Eyelid cancer","SCC","2026-06-15",{"date":113,"type":114},"2026-06-16","ACTUAL",{"date":116,"type":114},"2022-04-01",{"date":118,"type":87},"2028-01",{"name":5,"class":6},2]